Sosne G, Qiu P, Kurpakus-Wheater M
Why the shade varies between vials Even within the same formulation from the same pharmacy, you might notice slight color differences between batches
Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis/Bladder Pain Syndrome is defined as An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes. An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes. Over the years, this diagnosis has changed dramatically from how it is defined to approaching treatment
The agency's own scientists had already reviewed the data and recommended against it, proposing "not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List" [12]